Travere Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results

Posted: February 24, 2023 at 12:14 am

Recently received U.S. FDA accelerated approval of FILSPARI™ (sparsentan), the first and only non-immunosuppressive therapy for the reduction of proteinuria in IgA nephropathy (IgAN)

Here is the original post:
Travere Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results

Related Posts